PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Until recently, systemic chemotherapy was the only option for treating bladder cancer and outcomes remained dismal. After a long gap of no progress for 40 years, immuno-therapy with checkpoint inhibitors (PDL1 and PD1) has revolutionized the treatment paradigm of bladder cancer, with five approved agents to treat platinum-refractory bladder cancer since the first approval of atezolizumab in May 2016. METHODS: This review summarizes the most recent data on approved checkpoint inhibitors currently used in management of advanced bladder cancer. Early- and late-phase trials of the five checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab) in advanced bladder cancer are reviewed in detail. This review also describes the potential application of PD1/PDL1 inhibitors in adjuvant and neoadjuvant settings and non-muscle-invasive bladder cancer, as well as with radiation in muscle-invasive bladder cancer treatment. The role of PDL1 and tumor-mutation burden and clinical considerations in choosing a particular immunotherapy are also discussed. RESULTS: The approved checkpoint inhibitors (PD1 and PDL1 inhibitors) have similar efficacy and safety profiles in metastatic platinum-refractory bladder cancer, but they vary in dose and frequency and cost burden. However, only pembrolizumab has shown superiority over standard chemotherapy in a randomized Phase III setting so far. In addition, in the first-line setting for cisplatin-ineligible patients, both pembrolizumab and atezolizumab are US Food and Drug Administration-approved and well tolerated. There is a lack of consensus on the utility of testing for PDL1 as a predictive biomarker, as patients with no PDL1 expression also derive some clinical benefit. Tumor-mutation burden is another predictive biomarker, but needs further validation. CONCLUSION: Immunotherapy has offered a glimmer of hope to patients with bladder cancer. The current landscape is rapidly evolving, with novel immunotherapy-combination trials to improve outcomes further and evaluate predictive biomarkers to help identify patients most likely to benefit from such therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, PD-L1-negative tumors can still occasionally respond to anti-PD-1 therapy, and high PD-L1 expression, although correlative, is by no means sufficient for generating a response following anti-PD-1 therapy, indicating that other factors are involved in determining response and nonresponse to ICIs (80)(81)(82).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Bladder tumors have the third-highest rate of somatic mutations and are highly antigenic.(16) Additionally, therapeutic agents can be placed in direct contact with the tumor through intravesical administration, allowing a high concentration of the agent to be delivered with limited systemic exposure.”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · cited 1×
“17–19 It is also possible to monitor treatment response through direct surveillance of the tumor and related cells and biomarkers.”
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“The presence of certain bacteria in human microbiota (eg, commensal Bifidobacterium and Akkermansia muciniphila) is associated with an active immunoresponse when they are present in patients being treated with immunocheckpoint inhibitors.(47,48) Absence of these activating microbiota may result in an ineffective respo…”
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 4×
“The IMvigor 210 clinical study was a Phase II, multicenter, open-label trial of atezolizumab with two cohorts and provided the evidence for the FDA-approval decisions.(19,32) Cohort 1 included advanced UC patients who were ineligible O nc oT ar ge ts a nd T he ra py d ow nl oa de d fr om h ttp s: //w w w .”
InfluentialPembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · cited 2×
“4%).(26) Treatment-related AEs occurred in 60.”
Cited by
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, H. T., Lee, S. H., & Heo, Y.-S. (2019) · Molecules · doi:10.3390/molecules24061190 · Cited by 233
Mechanisms of immune evasion in bladder cancer
Crispen, P. L., & Kusmartsev, S. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02443-4 · Cited by 220
O'Donnell, P. H., Milowsky, M. I., Petrylak, D. P., Hoimes, C. J., Flaig, T. W., Mar, N., Moon, H. H., Friedlander, T. W., McKay, R. R., Bilen, M. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02887 · Cited by 196
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Harris, M. A., & Hawkins, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073817 · Cited by 160
Current and future perspectives of PD-1/PDL-1 blockade in cancer immunotherapy
Makuku, R., Khalili, N., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Journal of Immunology Research · doi:10.1155/2021/6661406 · Cited by 136
“Apart from melanoma, PD-1 inhibitors have also shown clinical efficacy in both solid and liquid cancers such as bladder, pancreatic, and non-small-cell lung cancer (NSCLC), follicular B cell, and non-Hodgkin lymphoma [45] (Table 2).”
BackgroundKraman, M., Faroudi, M., Allen, N. L., Kmiecik, K., Gliddon, D., Seal, C. J., Koers, A., Wydro, M. M., Batey, S., Winnewisser, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3548 · Cited by 115
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Zhang, Z., Yu, Y., Zhang, Z., Li, D., Liang, Z., Wang, L., Chen, Y., Liang, Y., & Niu, H. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02900-0 · Cited by 123
“In addition, a large proportion of patients are considered unsuitable for platinum-based chemotherapy due to comorbidities [5].”
BackgroundKEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC
Kamat, A. M., Shore, N. D., Hahn, N. M., Alanee, S. R., Nishiyama, H., Shariat, S. F., Nam, K., Kapadia, E., Frenkl, T. L., & Steinberg, G. D. (2020) · Future Oncology · doi:10.2217/fon-2019-0817 · Cited by 95
Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives
Leow, J. J. J., Liu, Z., Tan, T. W., Lee, Y. M., Yeo, E. K. S., & Chong, Y.-L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s225301 · Cited by 74
“Peri-Operative Systemic Therapy – Immunotherapy Checkpoint inhibitors have been extensively investigated in recent years, in part due to favorable objective response rates compared to standard of care chemotherapy.(90,91) Approved immunotherapeutic agents for urothelial carcinomas include the following 5 checkpoint in…”
BackgroundYap, T. A., LoRusso, P. M., Wong, D. J. L., Hu‐Lieskovan, S., Papadopoulos, K. P., Holz, J.-B., Grabowska, U. B., Grădinaru, C., Leung, K.-M., Marshall, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1449 · Cited by 56
Fierro, J., DiPasquale, J., Perez, J., Chin, B., Chokpapone, Y. M., Tran, A., Holden, A., Factoriza, C., Sivagnanakumar, N., Aguilar, R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06430-1 · Cited by 57
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
Sagawa, R., Sakata, S., Gong, B., Seto, Y., Takemoto, A., Takagi, S., Ninomiya, H., Yanagitani, N., Nakao, M., Mun, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.153323 · Cited by 55
“Despite that PD-L1 expression is considered a predictive biomarker for αPD-1/αPD-L1 treatment (42), cases with discordance between the pretreatment PD-L1 IHC score and treatment responsiveness are frequently seen in clinical situations, which is a major problem (43, 44).”
BackgroundGermanà, E., Pepe, L. R., Pizzimenti, C., Ballato, M., Pierconti, F., Tuccari, G., Ieni, A., Giuffrè, G., Fadda, G., Fiorentino, V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126750 · Cited by 53
“Moreover, up to 30–50% of patients with metastatic urothelial carcinoma are ineligible to receive cisplatin due to comorbidities [10].”
BackgroundBrower, B., McCoy, A. S., Ahmad, H., Eitman, C., Bowman, I. A., Rembisz, J., & Milowsky, M. I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1326715 · Cited by 49
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors
Sun, J., Zheng, Y., Mamun, M., Li, X., Chen, X., & Gao, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110504 · Cited by 51
Nishiyama, H., Yamamoto, Y., Sassa, N., Nishimura, K., Fujimoto, K., Fukasawa, S., Yokoyama, M., Enokida, H., Takahashi, K., Tanaka, Y., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01545-4 · Cited by 42
“The potential of immunotherapy in bladder cancer treatment has been known for approximately 30 years, since the efficacy of using intravesical bacillus Calmette–Guérin to provoke an immune response to treat certain types of bladder cancer was identified [11].”
BackgroundInfluentialLyu, Q., Lin, A., Cao, M., Xu, A., Luo, P., & Zhang, J. (2020) · Cancer Control · doi:10.1177/1073274820976665 · Cited by 40
“Similarly, multiple clinical trials have suggested that the overall response rate of highgrade or metastatic bladder tumors to ICIs fluctuates between 15% and 29%.(10) There is a clinical need for biomarkers to identify optimal candidates for ICIs.”
BackgroundRobu, S., Richter, A., Gosmann, D., Seidl, C., Leung, D. K.-W., Hayes, W., Cohen, D., Morin, P. E., Donnelly, D. J., Lipovšek, D., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.258384 · Cited by 40
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation
on behalf of the German Study Group of Bladder Cancer (DFBK e.V.), Morsch, R., Rose, M., Maurer, A., Cassataro, M. A., Braunschweig, T. A., Knüchel, R., Vögeli, T., Ecke, T., Eckstein, M., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06727-2 · Cited by 41
“pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab, have been assessed in clinical trials of advanced bladder cancer during the last years [7] and can be used for second line treatment, but only pembrolizumab and atezolizumab are currently approved by the Food and Drug Administration (FDA) and the Europe…”
PD‑L1/PD‑1 blockade in breast cancer: The immunotherapy era (Review)
Li, C.-J., Lin, L., Hou, M., & Chu, P. (2020) · Oncology Reports · doi:10.3892/or.2020.7831 · Cited by 42
“cancer, bladder cancer, chondrosarcoma, melanoma, and renal cell carcinoma were revealed to be 18, 28 and 27%, respectively (35,73-76).”
BackgroundThe Emerging Use of Immune Checkpoint Blockade in the Adjuvant Setting for Solid Tumors: A Review
Moujaess, E., Haddad, F., Eid, R., & Kourié, H. R. (2019) · Immunotherapy · doi:10.2217/imt-2019-0087 · Cited by 41
Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer
Wucherpfennig, S., Rose, M., Maurer, A., Cassataro, M. A., Seillier, L., Morsch, R., Hammad, E., Baldia, P. H., Ecke, T., Vögeli, T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111547 · Cited by 41
“Recently, immune checkpoint inhibitors (ICI) have evolved as a new therapeutic concept for several cancers and have now become an integral part of first-line (in platinum-ineligible patients) and second-line therapy of advanced (urothelial) bladder cancer [10].”
BackgroundExploring immune checkpoint inhibitors: Focus on PD-1/PD-L1 axis and beyond
Aden, D., Zaheer, S., Sureka, N., Trisal, M., Chaurasia, J. K., & Zaheer, S. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155864 · Cited by 41
Urobiome in Gender—Related Diversities of Bladder Cancer
Bilski, K., Dobruch, J. T., Kozikowski, M., Skrzypczyk, M., Oszczudłowski, M., & Ostrowski, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124488 · Cited by 33
Anti-Cancer Effects and Tumor Marker Role of Glutathione S-Transferase Mu 5 in Human Bladder Cancer
Jou, Y., Wang, S., Dia, Y.-C., Wang, S., Yu, M., Yang, H., Chen, L.-C., Shen, C., & Liu, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063056 · Cited by 33
“Recently, immunotherapy has provided hope for the treatment of metastatic platinum‐refractory bladder cancer but is only effective in patients with programmed cell death 1 ligand 1‐positive status [3].”
BackgroundImmune escape mechanisms and immunotherapy of urothelial bladder cancer
Yang, Z., Xu, Y., Bi, Y., Zhang, N., Wang, H., Xing, T., Bai, S., Shen, Z., Naz, F., Zhang, Z., et al. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202104.009 · Cited by 35
Xie, H., Rutz, J., Maxeiner, S., Grein, T., Thomas, A., Juengel, E., Chun, F. K. ‐., Cinatl, J. J., Haferkamp, A., Tsaur, I., et al. (2022) · Cancers · doi:10.3390/cancers14194682 · Cited by 32
“Immune checkpoint inhibitors targeting programmed death 1 (PD1) and programmed death-ligand 1 (PD-L1) have recently revolutionized the therapeutic paradigm of platinum-refractory bladder carcinoma [6].”
BackgroundRichters, A., Mehra, N., Meijer, R. P., Boormans, J. L., van der Heijden, A. G., Smilde, T. J., van der Heijden, M. S., Kiemeney, L. A. L. M., & Aben, K. K. H. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100266 · Cited by 32
RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis
Ho, S., Lee, Y., Ittmann, M., Lin, F., Chan, K. S., & Lin, W.-C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.008 · Cited by 31
Zhang, Z., Yu, Y., Zhang, P., Ma, G., Zhang, M., Liang, Y., Jiao, W., & Niu, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08229-1 · Cited by 29
“were still the only treatment option, with no inspiring effect on clinical outcomes [25].”
BackgroundCurrent and Emerging Strategies to Treat Urothelial Carcinoma
Rani, B., Ignatz-Hoover, J. J., Rana, P. S., & Driscoll, J. J. (2023) · Cancers · doi:10.3390/cancers15194886 · Cited by 29
“These approvals have opened new treatment options for patients with disease progression after platinum-based chemotherapy, those who are not eligible for first-line cisplatin-based therapy and have PD-L1-positive tumors, and those who are not suitable candidates for platinum-based therapy [108,109].”
BackgroundStrategies for Overcoming Immune Evasion in Bladder Cancer
Shin, J., Park, J. Y., Kim, S. W., Lee, J., Choi, W. S., & Kim, H. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063105 · Cited by 30
“Over the last 20 years, various groundbreaking immunotherapy strategies have been spotlighted in cancer treatment, such as PD-L1/PD-1 checkpoint inhibitors [9,10].”
BackgroundKearney, M., Zhang, L., Hubscher, E. M., Musat, M. G., Harricharan, S., & Wilke, T. (2023) · Future Oncology · doi:10.2217/fon-2023-0298 · Cited by 26
STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer
Sun, J., Wei, X., You, J., Yue, W., Ouyang, J., Ling, Z., & Hou, J. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s329723 · Cited by 30
“years, second-line immunotherapy with immune checkpoint inhibitors (ICIs) has been established and is still being studied in BLCA treatment.(6) Several multi-center randomized controlled trials have demonstrated that these ICIs such as PD1/PDL1 inhibitors showed superior clinical benefits over chemotherapy.”
BackgroundAdam, T., Becker, T. M., Chua, W. M., Bray, V., & Roberts, T. L. (2021) · Cancers · doi:10.3390/cancers13020277 · Cited by 27
“Urothelial carcinoma (UC) of the bladder accounts for 90% of all urothelial cancers with the remaining 10% in the ureter, urethra and urachus [28].”
BackgroundSun, X., Sun, J., Yuan, W., Gao, X., Fu, M., Xue, A., Li, H., Shu, P., Fang, Y., Hou, Y., et al. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04860-8 · Cited by 23
Baker, S. C., Mason, A. S., Slip, R. G., Eriksson, P., Sjödahl, G., Trejdosiewicz, L. K., & Southgate, J. (2022) · Cancers · doi:10.3390/cancers14215295 · Cited by 24
“Indeed, blocking antibodies against PD-L1 have been trialled clinically to disinhibit tumour-specific cytotoxic lymphocytes, but with limited success [20].”
BackgroundMiyake, M., Hori, S., Ohnishi, S., Toritsuka, M., Fujii, T., Shimizu, T., Owari, T., Morizawa, Y., Gotoh, D., Itami, Y., et al. (2019) · Cancer Science · doi:10.1111/cas.14158 · Cited by 21
Ruf, P., Bauer, H. W., Schoberth, A., Kellermann, C., & Lindhofer, H. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02930-7 · Cited by 22
Biomarkers in muscle invasive bladder cancer
Wilson, F., Joseph, N., & Choudhury, A. (2022) · Advances in clinical chemistry · doi:10.1016/bs.acc.2021.07.005 · Cited by 22
Lucchesi, C. A., Vasilatis, D. M., Mantrala, S., Chandrasekar, T., Mudryj, M. M., & Ghosh, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411395 · Cited by 23
Flores-Martín, J. F., Perea, F., Ruíz, M. E., Carretero, F., Rodríguez, T., Villamediana, M., Ruiz‐Cabello, F., Garrido, F., Cozar-Olmo, J. M., & Aptsiauri, N. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07371-2 · Cited by 24
Shafi, S., Aung, T. N., Xirou, V., Gavrielatou, N., Vathiotis, I. A., Fernandez, A. I., Moutafi, M. K., Yaghoobi, V., Herbst, R. S., Liu, L. N., et al. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00796-6 · Cited by 23
Sun, X., Shu, P., Fang, Y., Yuan, W., Zhang, Q., Sun, J., Fu, M., Xue, A., Gao, X., Shen, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.789915 · Cited by 18
Deng, X., Liu, X., Hu, B., Liu, J., Fu, B., & Zhang, W. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5217 · Cited by 22
“However, similar to other cancer types, only a small percentage of individuals may benefit from this treatment (6).”
Xu, P., Shen, P., Jin, Y., Wang, L., & Wu, W. (2019) · Europe PMC (PubMed Central) · Cited by 17
Clinical Utility of 18F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma
Das, J. P., Vargas, H. A., Ghafoor, S., Goh, A. C., & Ulaner, G. A. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.251561 · Cited by 18
Okuneye, K., Bergman, D. R., Bloodworth, J. C., Pearson, A. T., Sweis, R. F., & Jackson, T. L. (2021) · Computational and Systems Oncology · doi:10.1002/cso2.1019 · Cited by 21
“After nearly four decades of little progress, immunotherapy with checkpoint inhibitors (PD-L1 and PD-1) has fundamentally shifted the treatment paradigm of bladder cancer [50].”
BackgroundZhang, Y., Dong, X., Bai, L., Shang, X., & Zeng, Y. (2020) · Oncology Letters · doi:10.3892/ol.2020.12180 · Cited by 17
Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
Pinard, C. J., Hocker, S. E., Poon, A. C., Inkol, J. M., Matsuyama, A., Wood, R. D., Wood, G. A., Woods, J. P., & Mutsaers, A. J. (2021) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2021.110367 · Cited by 18
Liu, Z., Liu, X., Liu, F., Zhao, H., Zhang, Y., Wang, Y., Ma, Y., Wang, F., Zhang, W., Petinrin, O. O., et al. (2022) · Gene · doi:10.1016/j.gene.2022.146657 · Cited by 16
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Qian, X., Wang, H., & Yan, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963533 · Cited by 15
“Mainly two kinds of immune checkpoint inhibitors are currently applied in clinic, including CTLA-4 inhibitors (2) and PD-1/ PD-L1 inhibitors (3).”
BackgroundHussein, O., Rayan, M., Matarid, T. R., Elkhalifa, D. H., Abunada, H. H., Therachiyil, L., Khalil, A. A., Shahab Uddin, M. S., Maccalli, C., & Korashy, H. M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03514-4 · Cited by 16
Xu, J., Shen, D., Zhang, T., Wang, J., De, W., & Zhang, J. (2022) · Polish Journal of Pathology · doi:10.5114/pjp.2021.114177 · Cited by 14
“Clinical trials of PD1/PD-L1 inhibitors showed very promising results with durable responses [3, 7, 8, 9, 10, 11, 12].”
BackgroundPD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium
Dowell, A. C., Munford, H., Goel, A., Gordon, N. S., James, N. D., Cheng, K. K., Zeegers, M. P., Ward, D. G., & Bryan, R. T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626748 · Cited by 14
“However, whilst 15%–29% of patients exhibit an objective response to checkpoint inhibitors, the majority of patients fail to respond (3).”
BackgroundImmunotherapy for Stage III NSCLC: Durvalumab and Beyond
Fitzpatrick, O., & Naidoo, J. (2021) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s305466 · Cited by 17
Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer
Moussa, M. A., Papatsoris, A., Dellis, A., Chakra, M. A., & Saad, W. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1822743 · Cited by 13
Beyond liver cancer, more application scenarios for alpha-fetoprotein in clinical practice
Ma, C., Jin, Y., Wang, Y., Xu, H., & Zhang, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1231420 · Cited by 12
CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer
Smith, D. J., Lunj, S., Adamson, A. D., Nagarajan, S., Smith, T., Reeves, K. J., Hoskin, P., & Choudhury, A. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00901-y · Cited by 13
“However, some therapies such as PDL1 and FGFR3 inhibitors have been approved as second-line therapies for use following failure of first-line treatments 11 .”
InfluentialLim, S., Park, J.-H., & Chang, H. K. (2022) · Korean journal of urology · doi:10.4111/icu.20220031 · Cited by 11
“Moreover, even bladder cancer patients with high PD-L1 expression or tumor mutation burden often did not respond to PD-1/PD-L1 antibody treatment [12].”
Váradi, M., Horváth, O. N., Módos, O., Fazekas, T., Grunewald, C. M., Niegisch, G., Krafft, U., Grünwald, V., Hadaschik, B. A., Oláh, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-44103-9 · Cited by 12
“In this multicentric, retrospective study we examined real-world data in order (1) to assess the characteristics of ICI-treated urothelial cancer (UC) patients, (2) to examine the effectiveness of two widely used ICI agents (pembrolizumab and atezolizumab) comparing to respective randomized controlled trials (RCTs) an…”
MethodOvercoming cancer immunotherapy barriers via nanomaterial-mediated pyroptosis
Xie, J., Peng, B., Xiao, Y., Chen, X., Zhang, X., Chen, D., Song, L., Xu, M., Liao, W., & Zhang, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01024a · Cited by 11
Li, N., Zheng, H., Zheng, B., Chen, C., Cai, H., & Liu, M. (2020) · Cancer Management and Research · doi:10.2147/cmar.s248020 · Cited by 10
Xue, Y., Zhao, G., Pu, X., & Jiao, F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196802 · Cited by 9
“Frontiers in Oncology 02 Notably, studies have shown that targeting existed TEX markers, including PD-1/PD-L1 (18), CTLA-4 (19), T-cell immunoglobulin domain and mucin domain containing molecule-3 (TIM-3) (20), and T-cell immunoglobulin and ITIM domain (TIGIT) (21) pathways do not lead to complete recovery of T cell f…”
BackgroundWeiss, K. G., Gessner, K. H., Demzik, A. L., Moreton, E., Kim, W. Y., Wobker, S. E., Rose, T. L., Milowsky, M. I., & Bjurlin, M. A. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100779 · Cited by 9
“[39].”
Sexual dimorphism in bladder cancer: a review of etiology, biology, diagnosis, and outcomes
Zhu, S., & Zhao, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1326627 · Cited by 13
“In patients with advanced bladder cancer, the microbiota ’ s modulation affects how well they respond to systemic and adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy (Killock, 2018; Routy et al., 2018; Stenehjem et al., 2018; Zitvogel et al., 2018).”
BackgroundRole of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
Suh, J., & Yoo, S. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-758 · Cited by 11
“Recent advancements in the f ie ld of immuneoncological drugs have demonstrated their promising effects in advanced and metastatic settings (7), and there is accumulating evidence regarding the use of immunotherapy in treating the more indolent patient groups.”
Rose, M., Huth, S., Wiesehöfer, M., Ehling, J., Henkel, C., Steitz, J., Lammers, T., Kistermann, J., Klaas, O., Koch, M., et al. (2022) · Cancers · doi:10.3390/cancers14030488 · Cited by 9
“, bladder cancer [29]), d may also offer a promising approach to treating TNBC [30,31].”
BackgroundAljabery, F. A.-S., Liedberg, F., Häggström, C., Ströck, V., Hosseini, A., Gårdmark, T., Sherif, A. M., Jerlström, T., Malmström, P., Holmberg, L., et al. (2019) · Scandinavian Journal of Urology · doi:10.1080/21681805.2019.1681504 · Cited by 9
“Also, in the future, the use of checkpointinhibitors in the setting of cNþmight increase the possibilities of such induction treatment in patients with reduced renal function, potentially further improving outcomes [20].”
BackgroundImmunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
Kumar, U., Anthony, M. L., Sahai, R., Mittal, A., Durgapal, P., & Kishore, S. (2021) · Journal of Laboratory Physicians · doi:10.1055/s-0041-1736480 · Cited by 8
Dallinga, M. G., Bolhuis, K., Bins, A. D., & de Hoog, J. (2023) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000001402 · Cited by 7
Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies
Noel, O. D. V., Hassouneh, Z., Svatek, R. S., & Mukherjee, N. Z. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0414 · Cited by 8
Lin, D., Luo, S., Lin, S., Zhong, L., Zhou, W., Gu, D., Huang, X., Chen, Q., Xu, X., & Weng, X. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.10.001 · Cited by 9
Epithelioid inflammatory myofibroblastic sarcoma: a case report and brief literature review
Dou, W., Guan, Y., Liu, T., Zheng, H., Feng, S., Wu, Y., Wang, X., & Liu, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1212529 · Cited by 7
“The PD-1/PD-L1 axis has also been reported to play an important role in the immune antitumor response (47, 48).”
BackgroundAlternative splicing regulation and its therapeutic potential in bladder cancer
Li, L., Jin, T., Hu, L., & Ding, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402350 · Cited by 8
“In recent years, the advent of immunotherapy, particularly programmed cell death protein 1 (PD-1) and programmed-death ligand 1 (PD-L1) inhibitors, has presented new therapeutic opportunities for patients with bladder cancer (2).”
BackgroundSpecific antitumour immunity and mechanisms of tumour escape from immunological surveillance
Султанбаев, А. В., Тузанкина, И. А., Мусин, Ш. И., Kolyadina, I. V., Меньшиков, К. В., Султанбаев, М. В., Gilyazova, I. R., & Kudlay, D. A. (2024) · P A Herzen Journal of Oncology · doi:10.17116/onkolog20241306170 · Cited by 8
Grantzau, T. L., Toft, B. G., Melchior, L. C., Elversang, J., Stormoen, D. R., Omland, L. H., & Pappot, H. (2022) · Apmis · doi:10.1111/apm.13249 · Cited by 6
Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer
Huang, X., Wang, Q., Nan, Y., Zhang, X., Ke Cheng, X. U., Ju, D., & Ding, W. (2024) · Biomedicines · doi:10.3390/biomedicines12092152 · Cited by 5
“Results from clinical trials also showed that patients could benefit from systemic immunotherapy [4].”
BackgroundA Transformable Specific‐Responsive Peptide for One‐Step Synergistic Therapy of Bladder Cancer
Wang, Z., Qu, T., Zhang, Z., Zeng, F., Song, H., Zhang, K., Guo, P., Tong, Z., Hou, D., Liu, X., et al. (2024) · Small · doi:10.1002/smll.202310416 · Cited by 5
Anguera, G., Mulet, M., Zamora, C., Osuna‐Gómez, R., Joaquín, A. B., Sullivan, I., Serra-López, J., Cantó, E., Vidal, S., & Majem, M. (2024) · Biomedicines · doi:10.3390/biomedicines12050958 · Cited by 7
The Impact of Immune Checkpoint-Inhibitors Therapy in Urinary Bladder Cancer
Silva, A. L., Abreu‐Mendes, P., Martins, D. F., & Mendes, F. (2021) · Onco · doi:10.3390/onco1010002 · Cited by 5
“Involving 199 patients with locally advanced or inoperable metastatic urothelial carcinoma with progression after platinum-based chemotherapy in cohort 1, whilst in cohort 2 were patients receiving Atezolizumab as first-line therapy, due to ineligibility to cisplatin [9,55].”
BackgroundMethodResultInfluentialClinical utility of histopathology data: cancers of the testis and urinary bladder
Chan, R. C., Chandra, A., & Varma, M. (2021) · Diagnostic histopathology · doi:10.1016/j.mpdhp.2021.04.004 · Cited by 5
Nordstrom, B. L., Oguz, M., Chu, B. C., Ouwens, M., Arkenau, H.-T., & Klein, A. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2019-0163 · Cited by 5
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need
Montazeri, K., & Sonpavde, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1855981 · Cited by 5
Gupta, S., & Kamat, A. M. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0357-1 · Cited by 5
Self-citationShining light on immunotherapy in metastatic urothelial carcinoma: trends and prospects
Shah, B. A., Sardar, A., Li, Y., & Yang, B. (2025) · MedMat. · doi:10.1097/mm9.0000000000000025 · Cited by 6
PD-L1 knockout or ZG16 overexpression inhibits PDAC progression and modulates TAM polarization
Meng, H., Nan, M., Li, Y., Ding, Y., Fang, X., Ma, W., & Zhang, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1510179 · Cited by 4
Mohta, A., Arora, A., & Jain, S. K. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14889 · Cited by 4
Kerr, P. S., Freedland, S. J., & Williams, S. B. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1665509 · Cited by 4
Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma
Bowen, S. G., Allison, D. B., Hensley, P. J., & Myint, Z. W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1608291 · Cited by 4
Comparison of PD-L1 detection methods, platforms and reagents in bladder cancer
Weng, M., Bai, Y., Xu, L., Chang, C., & Teng, X. (2022) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2022.151986 · Cited by 3
Sun, K., Zhang, Z., Wang, D., Huang, Y., Zhang, J., & Lian, C. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e14334 · Cited by 3
“Currently, the therapeutic targeting of programmed cell death 1 (PD1) and programmed cell death 1 ligand 1 (PDL1) reduces tumor volume and improves the prognosis in multiple types of cancer [11 – 13].”
Tislelizumab, a novel PD-1 monoclonal antibody in urothelial cancer: A real-world study
Wang, Z., Bi, H., Wang, Y. D., Liu, Q., Shao, B., Li, C. Q., Fu, C., Fu, S., Shan, G., Chen, A., et al. (2023) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2023.12.006 · Cited by 3
Asakawa, K., Waratani, M., Massey, O., Holbrook, T., Kondō, M., Saito, A., & Nishiyama, H. (2024) · International Journal of Urology · doi:10.1111/iju.15450 · Cited by 3
The role of modern immunotherapy in metastatic urothelial cancer: mini review
Jackson‐Spence, F., Toms, C., Yang, Y.-H., Jurascheck, L., Choy, J., Flanders, L., Szabados, B. E., & Powles, T. B. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.50 · Cited by 3
Horibe, Y., Nakata, W., Tsujimura, G., Tsujimoto, Y., Gotoh, T., & Tsujihata, M. (2021) · Urology Case Reports · doi:10.1016/j.eucr.2021.101959 · Cited by 3
Metadata
- Authors
- Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S.
- Affiliations
- University of Minnesota (US)
- Corresponding author
- Gupta, Shilpa
- Venue
- OncoTargets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2018-09
- Volume
- Volume 11
- Pages
- 5973-5989
- ISSN
- 1178-6930 (ISSN-L)
- PMC
- PMC6157986
- OpenAlex
- W2890398072
- Cited by
- 144
- References
- 47
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 26 · 2023: 20 · 2022: 19 · 2021: 25 · 2020: 25 · 2019: 10 · 2018: 2
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- OncoTargets and Therapy (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Urinary and Genital Oncology Studies
- Keywords
- PD-1 inhibitors, PD-L1 inhibitors, bladder urothelial carcinoma, immune checkpoint inhibitors, pembrolizumab, nivolumab, atezolizumab, durvalumab, avelumab, adjuvant immunotherapy, neoadjuvant immunotherapy, non-muscle-invasive bladder cancer, muscle-invasive bladder cancer, radiotherapy, tumor mutational burden, predictive biomarkers, combination immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.